Idiopathic pulmonary fibrosis: state of the art for 2023
European Respiratory Journal · 2023-04 · 61 (4) · 2200957
DOI: 10.1183/13993003.00957-2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 26.01.2023. Verfasst von Anna J Podolanczuk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Lung Transplantation. Die Arbeit wurde bisher 367-mal zitiert (Crossref) und nennt 189 Literaturangaben.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by worsening respiratory symptoms and physiological impairment. Increasing awareness of the clinical manifestations of IPF, more widespread use of computed tomography scans and other potential factors have contributed to a rising prevalence of IPF over the last two decades, especially among people over the age of 65 years. Significant advances in the understanding of the pathobiology of IPF have emerged, and multiple genetic and nongenetic contributors have been identified. The individual patient course and the rate of disease progression in IPF are often unpredictable and heterogeneous. The rate of lung function decline is further modified by treatment with antifibrotic therapies, which have been shown to slow down disease progression. The presence of comorbid conditions may increase symptom burden and impact survival. Clinical monitoring at regular intervals to assess for disease progression by worsening symptoms, physiological parameters and/or radiological features is essential to assess the natural disease course and to guide further management, including prompt detection of complications and comorbid conditions that warrant additional treatment considerations, and timely consideration of referral to palliative care and lung transplantation for the appropriate patient. More studies are needed to determine whether early detection of IPF might improve patient outcomes. The purpose of this concise clinical review is to provide an update on IPF diagnosis, epidemiology, natural history and treatment in the context of new knowledge and latest clinical practice guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
- Division of Pulmonary and Critical Care, Department of Medicine, Mount Auburn Hospital/Beth Israel Lahey Health, Harvard Medical School, Boston, MA, USA.
- Department of Thoracic Imaging, University of Lille, Lille, France.
- Division of Pulmonary Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Respiratory Medicine, Pathology and Molecular Medicine, McMaster University and St Joseph's Healthcare, Hamilton, ON, Canada.
- Department of Medicine and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA graghu@uw.edu.
ORCID-Profile: Anna J Podolanczuk, Martin Kolb
Zitieren
APA
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023). Idiopathic pulmonary fibrosis: state of the art for 2023. European Respiratory Journal, 61(4), 2200957. https://doi.org/10.1183/13993003.00957-2022
Vancouver
Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. European Respiratory Journal. 2023;61(4):2200957. doi:10.1183/13993003.00957-2022
BibTeX
@article{Podolanczuk2023,
author = {Podolanczuk, Anna J and Thomson, Carey C and Remy-Jardin, Martine and Richeldi, Luca and Martinez, Fernando J and Kolb, Martin and Raghu, Ganesh},
title = {Idiopathic pulmonary fibrosis: state of the art for 2023},
journal = {European Respiratory Journal},
year = {2023},
volume = {61},
number = {4},
pages = {2200957},
doi = {10.1183/13993003.00957-2022}
}
EUVIMED